12th week of 2009 patent applcation highlights part 39 |
Patent application number | Title | Published |
20090074710 | METHOD OF TREATMENT USING A CYTOKINE ABLE TO BIND IL-18BP TO INHIBIT THE ACTIVITY OF A SECOND CYTOKINE - The present invention relates to the use of a cytokine-1, preferably from the IL-1 family more preferably IL-1F7b, or an isoform, mutein, fused protein, functional derivative or fragment thereof capable of binding to IL-18BP or a mutein, fused protein, functional derivative or fragment thereof and capable of inhibiting a receptor of a cytokine-2, cytokine-2 being a member of the IL-1 family, preferably IL-18, in the manufacture of a medicament for the treatment or prevention of a disease which is caused or aggravated by inducing said receptor of cytokine-2. | 2009-03-19 |
20090074711 | HUMAN THERAPIES USING CHIMERIC AGONISTIC ANTI-HUMAN CD40 ANTIBODY - Methods of human therapy using a chimeric anti-CD40 antibody, LOB 7/4 or humanized variants thereof, are provided. This CD40 antibody elicits agonistic effects on immunity when used as a monotherapy especially when used in the treatment of human lymphomas and leukemias and other solid tumors In addition, this agonistic CD40 antibody when administered in combination with certain molecules such as TLR agonists or interferons, e.g., alpha and beta interferon, elicits a synergistic effect on immunity. | 2009-03-19 |
20090074712 | Methods for Treatment and Prevention of Infection - Specific cytokines may be used as agents for the treatment and/or prevention of bacterial infection, by binding to components of the bacterial cell membrane and directly killing the bacteria. This finding has a number of applications in screening methods, vaccine production and clearance of bacterial components. | 2009-03-19 |
20090074713 | DENDRITIC CELL TUMOR INJECTION (DCTI) THERAPY - The invention relates to a method of treating tumor cells within a patient wherein immature dendritic cells developed from the patient's monocyte cells and a lymphocyte cultured medium (LCM) adjuvant are introduced into the patient directly into the patient's tumor cells. The immature dendritic cells and LCM adjuvant combine with the antigens in the tumor cells to form a cancer vaccine, thereby immediately treating the tumor cells of the patient. The invention also provides a precursor treatment step of treating the patient with radiation therapy or a chemotherapy regimen. | 2009-03-19 |
20090074715 | Compounds for the Treatment of Hepatitis C - The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. | 2009-03-19 |
20090074716 | METHOD FOR TREATING INFLUENZA VIRUS INFECTION - The invention concerns the treatment of orthomyxovirus infections with inhibitors of the ubiquitin protease system, in particular proteasome inhibitors. | 2009-03-19 |
20090074717 | Anti-viral compounds, compositions, and methods of use - Disclosed are compounds of Formula (I), pharmaceutically acceptable salts and solvates thereof, compositions thereof, and methods for their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses. | 2009-03-19 |
20090074718 | Avian derived erythropoietin - Erythropoietin obtained from eggs laid by transgenic avians having avian N-linked and O-linked glycosylation patterns. | 2009-03-19 |
20090074719 | Peptides, Peptidomimetics and Small Molecule Inhibitors of the Epstein-Barr Virus Mediated Fusion and Entry Process - Disclosed are compositions and methods for modulating Epstein-Barr virus (EBV) infection in a patient. The compositions may include peptides or peptidomimetics that are related to gp42 and function to inhibit EBV-mediated membrane fusion. | 2009-03-19 |
20090074720 | METHODS FOR DECREASING IMMUNE RESPONSE AND TREATING IMMUNE CONDITIONS - The present invention relates to compositions and methods for decreasing an immune response in an animal comprising administering to said animal an agent that binds a bioactive lipid and reduces the effective concentration of said bioactive lipid. Also provided are methods for treating diseases or conditions, including autoimmune disorders, which are characterized by an aberrant, excessive or undesired immune response. The methods of the invention utilize agents that bind bioactive lipids and are capable of decreasing the effective concentration of the bioactive lipid. In some embodiments, the agent is a monoclonal antibody that is reactive against sphingosine-1-phosphate (S1P) or lysophosphatidic acid (LPA). | 2009-03-19 |
20090074721 | METHODS FOR TREATING VIRAL INFECTION WITH ORAL OR INJECTIBEL DRUG SOLUTION - Pharmaceutical composition comprising compounds and/or compositions useful to inhibit viral replication are disclosed. | 2009-03-19 |
20090074722 | Products and methods for treating PTP lar diseases - The present invention relates to methods and products useful for the treatment of various epithelial cell migration diseases and disorders, and to methods useful for the identification of various products useful for the treatment of these diseases and disorders. In particular, methods for treating using PTP LAR are described, as are methods for identifying compounds to modulate PTP LAR activity. | 2009-03-19 |
20090074723 | Method of Treating or Retarding the Development of Blindness - A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method. | 2009-03-19 |
20090074724 | MATERIALS AND METHODS FOR INHIBITING WIP1 - Isolated or purified oligonucleotides and isolated or purified morpholino oligomers; a method of detecting cancer or a predisposition to cancer in a mammal, comprising comparing the level of expression of Wip1 in the mammal to a control; a method of treating cancer in a mammal that expresses the same or a higher level of Wip1 as compared to a mammal of the same species that does not have cancer, comprising administering to the mammal a cancer-treating effective amount of a Wip1 inhibitor; a method of screening an oligonucleotide or morpholino oligomer for the ability to inhibit the expression of Wip1; a method of determining the efficacy with which a test oligonucleotide or morpholino oligomer inhibits Wip1 expression; a method of screening a compound for Wip1-inhibiting activity; and a method of determining the efficacy with which a test compound inhibits Wip1. | 2009-03-19 |
20090074725 | Live organism product - A live organism product wherein the organisms are in a dormant state and are suspended in a liquid carrier which is sufficiently devoid of moisture so that the organisms will remain in a dormant state for several months. The carrier is comprised of oil. The carrier may also include an absorbent. The product is stored and shipped in a plastic bag and is sprayed onto its target host or the like. The moisture and pH then activates the organisms. | 2009-03-19 |
20090074726 | MVA EXPRESSING MODIFIED HIV ENVELOPE, GAG, AND POL GENES - The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes. | 2009-03-19 |
20090074727 | METHOD OF TREATING SOLID TUMOR - The present invention provides a method of immune/gene combination therapy that has an effect of suppressing growth of an intractable solid tumor and is useful for treatment of such a tumor, and a therapeutic composition used for said method. | 2009-03-19 |
20090074728 | Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase - The present invention relates to the use of tissue non-specific alkaline phosphatase (TNAP) as a marker for identifying and/or isolating adult multipotential cells. The present invention also relates to cell populations enriched by methods of the present invention and therapeutic uses of these cells. | 2009-03-19 |
20090074729 | AUGMENTATION AND REPAIR OF SPINCTER DEFECTS WITH CELLS INCLUDING FIBROBLASTS - An embodiment of the invention includes methods for the long-term augmentation and/or repair of skin defects (scars, skin laxness, skin thinning, and skin augmentation), cellulite, breast tissue, wounds and burns, urological and gastroesophageal sphincter structures, hernias, periodontal disease and disorders, tendon and ligament tears and baldness, by the injection or direct surgical placement/implantation of autologous cultured cells and/or cultured cell-produced extracellular matrix that is derived from connective tissue, dermis, fascia, lamina propria, stroma, adipose tissue, muscle, tendon, ligament or the hair follicle. The corrective application is done on tissue proximal or within the area of the defect. The method involves retrieving viable cells from the subject, a neonate or human fetus. Alternatively, the corrective application involves the cells placed in a matrix, preferably comprised of autologous extracellular matrix constituents as a three-dimensional structure or as a suspension, prior to placement into a position with respect to the subject's defect. In a further embodiment, the preferable autologous extracellular matrix constituents are collected from culture and placed in a position with respect to the subject's defect. | 2009-03-19 |
20090074730 | NOVEL STEM CELLS, NUCLEOTIDE SEQUENCES AND PROTEINS THEREFROM - The present invention provides novel stem cells, nucleotide sequences and proteins therefrom. More specifically, the present invention provides Pax7+/Myf5− stem cells and methods for identifying and isolating them. Also provided is a MEGF10 nucleotide sequence and protein. | 2009-03-19 |
20090074731 | METHOD OF ISOLATION AND USE OF CELLS DERIVED FROM FIRST TRIMESTER UMBILICAL CORD TISSUE - A method of isolating a pluripotent cell from human umbilical cord is described herein. The method involves collecting a sample of umbilical cord from fetal tissue obtained at less than 20 weeks of gestation, for example a first trimester umbilical cord. The sample is treated to obtain isolated umbilical cord cells, after which the isolated umbilical cord cells are incubated. Stem cells obtained in this way can be differentiated for use in therapeutic applications. | 2009-03-19 |
20090074732 | Scaffold for Cell Growth and Differentiation - The present invention provides a devitalized mammalian parenchymatous tissue composition which includes an interstitial structure which can serve as a scaffold for tissue repair or regeneration. The devitalized mammalian parenchymatous tissue composition can further include the basement membrane of the tissue. | 2009-03-19 |
20090074733 | THYMIDYLATE KINASE MUTANTS AND USES THEREOF - The invention relates to a composition comprising:
| 2009-03-19 |
20090074734 | MICROBIAL INTESTINAL DELIVERY OF OBESITY RELATED PEPTIDES - Microbial delivery of obesity related peptides is disclosed. Genetically modified yeasts and/or lactic acid bacteria are described for the delivery of neuropeptides and/or peptide hormones that play a role in stimulation or inhibition of food intake and/or energy homeostasis. | 2009-03-19 |
20090074735 | TOPICAL PRODUCT CONTAINING SACRIFICIAL MATERIAL FOR NEUTRALIZING FREE RADICALS - A topical product to protect the skin from free radicals is disclosed in one embodiment of the invention as including a carrier medium for topical application to the skin. A sacrificial material that is compatible with the skin is interspersed with the carrier medium. This sacrificial material may be selected to react with free radicals within the skin. The sacrificial material may be further selected to react with water to produce hydrogen (a powerful antioxidant) and a reaction product that is also compatible with the skin. In this way, both the sacrificial material and the hydrogen will react with free radicals to provide protection against free radicals. | 2009-03-19 |
20090074736 | IMPLANTABLE PREPARATIONS COMPRISING GLOBIN, PROCESS FOR THEIR PRODUCTION, AND USES - Preparations comprising, especially, globin that is insoluble at neutral pH, and therefore at physiological pH, in which the globin has been obtained from whole blood by depigmentation in a medium that extracts or dissolves the haem but leaves the globin and the other constituents of proteinic nature in a substantially undissolved state, a process for the production of those preparations, and uses, especially for the filling, healing or regeneration of tissues, especially for chronic wounds and osseous healing or regeneration. | 2009-03-19 |
20090074737 | COMPOSITIONS AND METHODS FOR PROLONGING SURVIVAL OF PLATELETS - The present invention provides modified platelets having a reduced platelet clearance and methods for reducing platelet clearance. Also provided are compositions for the preservation of platelets. The invention also provides methods for making a pharmaceutical composition containing the modified platelets and for administering the pharmaceutical composition to a mammal to mediate hemostasis. | 2009-03-19 |
20090074738 | 1-SUBSTITUTED-3-BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO-CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME - A compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-substituted-3-(β-D-glycopyranosyl) nitrogen-containing heterocyclic compound represented by the general formula (I), a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate thereof; an SGLT inhibitor containing the same; a pharmaceutical composition containing the same and a combination pharmacy of them. In the formula, A represents an alkylene group or alkenylene group; B represents a single bond, —O—, —S— or —NH—; C represents an optionally substituted aryl or heteroaryl group; Q independently represents a carbon atom which a hydrogen atom or a substituent binds to, or a nitrogen atom. | 2009-03-19 |
20090074739 | Pharmacological vitreolysis - A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy. | 2009-03-19 |
20090074740 | Use of haptoglobin genotyping in diagnosis and treatment of defective reverse cholesterol transport (RCT) - A method of determining a potential of a nondiabetic or diabetic patient to benefit from reverse cholesterol transport therapy for treatment of a vascular complication, followed by methods and compositions of treating the diagnosed vascular complications comprising determining a haptoglobin phenotype of the patient. Reverse cholesterol transport therapy includes inhibition of cholesteryl ester transport protein, such as by using the compound torcetrapib. | 2009-03-19 |
20090074741 | Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response - Telomerase peptides that bind MHC are disclosed. The instant application also discloses vaccines containing said peptides and methods of using said peptides to enhance a CTL response against mammalian cancer cells. | 2009-03-19 |
20090074742 | PROTEIN, OSTEOCLAST DIFFERENTIATION INHIBITOR, INFLAMMATORY BONE RESORPTION THERAPEUTIC AGENT, GENE, RECOMBINANT VECTOR, METHOD OF MANUFACTURING A PROTEIN, METHOD OF INHIBITING OSTEOCLAST DIFFERENTIATION, AND METHOD OF TREATING INFLAMMATORY BONE RESORPTION - There are provided a protein which comprises the amino acid sequence of an extracellular region of Ror2 and is water-soluble, an osteoclast differentiation inhibitor for inhibiting differentiation of a precursor cell of osteoclast into an osteoclast, which comprises the protein as described above, an inflammatory bone resorption therapeutic agent for treating inflammatory bone resorption, which comprises the protein as described above, a gene which codes a protein comprising the amino acid sequence of an extracellular region of Ror2 and being water-soluble, a recombinant vector which comprises the gene as described above, a method of manufacturing a protein, which comprises a step of causing expression of a gene coding a protein comprising the amino acid sequence of an extracellular region of Ror2 and being water-soluble in a microorganism to synthesize the protein and a step of extracting the protein from the microorganism into water or an aqueous solution, a method of inhibiting osteoclast differentiation, which uses the protein as described above, and a method of treating inflammatory bone resorption, which uses a protein as described above. | 2009-03-19 |
20090074743 | Inositol Pyrophosphates Determine Exocytotic Capacity - The invention provides reagents and methods for treating type II diabetes, as well as methods for identifying compounds for treating type II diabetes. | 2009-03-19 |
20090074744 | USE OF COLLAGENASE TO FACILITATE GUIDE WIRE CROSSING IN TOTAL ARTERIAL OCCLUSIONS - The use of a collagenase containing formulation for degrading collagen within an occlusive atherosclerotic plaque in a chronic fibrotic occlusion, chronically occluded animal tube or cavity. A medical-related apparatus is provided comprising a medical-related device having provided thereto a therapeutic amount of a collagen degrading composition comprising a proteiolytic enzyme containing formulation A method is provided for treating chronically occluded animal tubes and cavities by administering a therapeutic effective amount of a proteolytic enzyme-containing formulation adjacent to an occluding atherosclerotic plaque, waiting for a pre-angioplasty waiting period, followed by crossing the plaque with an angioplasty guide wire. | 2009-03-19 |
20090074745 | TREATMENT AND PREVENTION OF TISSUE DAMAGE - A method for the treatment or prevention of tissue damage in a subject having an inflammatory and/or tissue damaging condition, which comprises administering to the subject an effective amount of a compound capable of inhibiting the binding of C-reactive protein (CRP) to an autologous or extrinsic ligand. | 2009-03-19 |
20090074746 | Compounds to treat alzheimer's disease - The present invention is substituted amines of formula (X) | 2009-03-19 |
20090074747 | Methods and Compositions for Treating Allergic Diseases - Disclosed in the present invention are antibodies that specifically recognize and antagonize human TSLP receptor, and methods of employing these antibodies to treat or ameliorate diseases or disorder mediated by TSLP signaling. | 2009-03-19 |
20090074748 | Immunological control of beta-amyloid levels in vivo - Disclosed herein are compositions and methods useful for controlling β-amyloid levels. In particular, the instant invention relates to an antibody that catalyzes hydrolysis of β-amyloid at a predetermined amide linkage are provided. The present invention also provides a vectorized antibody that is capable of crossing the blood brain barrier and is also capable of catalyzing the hydrolysis of β-amyloid at a predetermined amide linkage. Also provided are methods for modulating β-amyloid levels in vivo using antibodies that bind to β-amyloid. These compositions and methods have therapeutic applications, including the treatment of Alzheimer's disease. | 2009-03-19 |
20090074749 | IMMUNOGLOBULIN G (IgG) CONCENTRATE DEPLETED OF ANTI-A AND ANTI-B ANTIBODIES AND OF POLYREACTIVE IgGs - The present invention relates to an immunoglobulin G concentrate for therapeutic use, in which the respective contents of anti-A and anti-B antibodies are in accordance with a negative result in the in vitro indirect Coombs test. This IgG concentrate also has a polyreactive IgG content of between 0.01% and 0.1%, in particular between 0.07% and 0.1%, relative to the total content of IgG. | 2009-03-19 |
20090074750 | REGULATOR OF BASAL CELLULAR CALCIUM CONCENTRATION AND METHODS OF USE - The invention features methods and compositions for determining states of basal intracellular calcium levels in a eukaryotic cell. Also provided are methods for identifying an agent (e.g., a gene product or small molecule compound) that modulates basal intracellular calcium levels (e.g., by modulating STIM-2 activity), as well as kits and systems for practicing the subject methods. | 2009-03-19 |
20090074751 | GROWTH FACTOR FRACTION COMPOSITIONS AND METHODS - Compositions and formulations are provided comprising a growth factor fraction and at least one glucan. Also provided are methods for making the compositions and formulations. Methods of promoting growth in an animal using the compositions and/or formulations are also provided. | 2009-03-19 |
20090074752 | Surrogate Therapeutic Endpoint For Anti-CTLA-4 Based Immunotherapy Of Disease - The present invention provides a method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided. | 2009-03-19 |
20090074753 | PLATELET-DERIVED GROWTH FACTOR COMPOSITIONS AND METHODS OF USE THEREOF - A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier. | 2009-03-19 |
20090074754 | Methods and compositions useful in the treatment of mucositis - In certain aspects, the present invention provides compositions and methods for treating mucositis. | 2009-03-19 |
20090074755 | Use of panton-valentine leukocidin for treating and preventing staphylococcus infections - The present invention relates to compositions and methods for treating | 2009-03-19 |
20090074756 | USE OF LLT1 AND/OR CD161 FOR MODULATTING THE ACTIVITY OF CELLS OF THE IMMUNE SYSTEM - The present invention relates to a method for modulating in vivo or in vitro the activity of cells expressing CD161 and/or LLT1, characterized in that said cells are contacted respectively with LLT1 or fragments thereof, and/or with or fragments thereof. | 2009-03-19 |
20090074757 | Antitumor Combination Comprising Substituted Acryloyl Distamycin Derivatives and Antibodies Inhibiting Growth Factors or Their Receptors - The present invention provides the combined use of acryloyl distamycin derivatives, in particular α-homo- and α-chloro-acryloyl distamycin derivatives of formula (I), as set forth in the specification, and an antibody inhibiting a growth factor or its receptor, in the treatment of tumors. Also provided is the use of the said combinations in the treatment or prevention of metastasis or in the treatment of tumors by inhibition of angiogenesis. | 2009-03-19 |
20090074758 | IL-17 receptor a antigen binding proteins - The present invention relates to IL-17 Receptor A antigen binding proteins, such as antibodies, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation. | 2009-03-19 |
20090074759 | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof - Small animal models for assessing immunomodulatory effects of compounds are provided. | 2009-03-19 |
20090074760 | USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT - The use of anti-CD20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related diseases, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients. | 2009-03-19 |
20090074761 | Therapeutic beta-glucan combinations - A therapeutic composition for treating a proliferative disorder includes a VEGF antagonist and β-glucan. VEGF is overexpressed in some tumor types. The efficacy of treatment with VEGF antagonists capable of activating complement in combination with β-glucan is significantly increased. | 2009-03-19 |
20090074762 | THERAPEUTIC USE OF ANTI-TWEAK RECEPTOR ANTIBODIES - Compositions and methods for treating solid tumors are provided herein. | 2009-03-19 |
20090074763 | METHOD FOR INHIBITING BONE RESORPTION - The invention is directed to a method of inhibiting bone resorption. The method comprises administering to a human an amount of sclerostin inhibitor that reduces a bone resorption marker level for at least 2 weeks. The invention also provides a method of monitoring anti-sclerostin therapy comprising measuring one or more bone resorption marker levels, administering a sclerostin binding agent, then measuring the bone resorption marker levels. Also provided is a method of increasing bone mineral density; a method of ameliorating the effects of an osteoclast-related disorder; a method of treating a bone-related disorder by maintaining bone density; and a method of treating a bone-related disorder in a human suffering from or at risk of hypocalcemia or hypercalcemia, a human in which treatment with a parathyroid hormone or analog thereof is contraindicated, or a human in which treatment with a bisphosphonate is contraindicated. | 2009-03-19 |
20090074764 | Methods for diagnosing and treating neuroendocrine cancer - The present invention relates to a method for diagnosing neuroendocrine cancers via detecting the presence of N-methyl D-asparate-associated (NMDA) glutamate receptors type 1 and/or type 2. Methods for preventing and treating neuroendocrine cancers are also disclosed. | 2009-03-19 |
20090074765 | INHIBITORS OF PLACENTAL GROWTH FACTOR FOR THE TREATMENT OF PATHOLOGICAL ANGIOGENESIS, PATHOLOGICAL ARTERIOGENESIS, INFLAMMATION, TUMOR FORMATION AND/OR VASCULAR LEAKAGE - The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF | 2009-03-19 |
20090074766 | Methods of inhibiting HIV-2 infection - This invention provides methods of inhibiting HIV-2 infection of a susceptible cell by HIV-2 which comprises subjecting the susceptible cell to an effective HIV-2 infection inhibiting dose of a humanized antibody designated PRO 140, or of an anti-CCR5 receptor monoclonal antibody, wherein the effective HIV- | 2009-03-19 |
20090074767 | Isolated human phosphodiesterase proteins, nucleic acid molecules encoding human phosphodiesterase proteins, and uses thereof - The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the phosphodiesterase peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the phosphodiesterase peptides, and methods of identifying modulators of the phosphodiesterase peptides. | 2009-03-19 |
20090074768 | Activin-actriia antagonists and uses for treating or preventing breast cancer - In certain aspects, the present invention provides compositions and methods for treating or preventing breast cancer in humans. | 2009-03-19 |
20090074769 | GLP-1 ANALOG FUSION PROTEINS - The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake. | 2009-03-19 |
20090074770 | Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and uses thereof - The present invention relates to amino acid sequences that binding to serum proteins such as serum albumin; to compounds, proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides, is essentially independent in the pH range 5 to 8. | 2009-03-19 |
20090074771 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof - The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention. | 2009-03-19 |
20090074772 | Anti-CD70 Antibody and Its Use for the Treatment of Cancer and Immune Disorders - Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering to a subject the CD70-binding agent. | 2009-03-19 |
20090074773 | CANCER VACCINE - The invention relates generally to the field of cancer diagnosis, prognosis, treatment and prevention. More particularly, the present invention relates to methods of diagnosing, treating and preventing lung cancer. In particular, aspects of the invention are directed to methods of diagnosing, treating and preventing small cell lung cancers. Methods of using a nucleic acid and/or a protein, which are differentially expressed in tumor cells, and antibodies immunospecific for the protein, to treat, diagnose and/or prevent said cancers, are provided for by the present invention. | 2009-03-19 |
20090074774 | Fgfr binding peptides - The present invention relates to new peptide compounds capable of direct binding to fibroblast growth factor receptor (FGFR) and activating said receptor. The compounds of the invention comprise peptide fragments of the neural cell adhesion molecule (NCAM) derived from the fibronectin type-III module 1 (F3, 1) of NCAM. Peptide sequences of the invention are capable of stimulating learning and memory and/or neurite outgrowth and/or neural cell survival. Peptide sequences and compounds comprising thereof, according to the invention, may be beneficially used for treatment and/or prevention of different pathological conditions wherein FGFR and/or NCAM play a role in pathology and/or recovery from disease. Accordingly, pharmaceutical compositions comprising the peptide sequences and compounds of the invention are also in the scope of protection. | 2009-03-19 |
20090074775 | Use Of Anti-AB Antibody To Treat Traumatic Brain Injury - A method of effectively treating traumatic brain injury is described. The method comprises administering an effective amount of an anti-Aβ antibody to a living mammalian biosystem such as to a human. An antibody useful in such treating includes an antibody that therapeutically attenuates the toxic effects of the Aβ peptide in a living mammal in relation to traumatic brain injury. | 2009-03-19 |
20090074776 | Human FGF-21 gene and gene expression products - This invention relates to human fibroblast growth factor (hF-GF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods of treating conditions related to thymic function, and methods of treating conditions of the testis. The invention also relates to mouse fibroblast growth factor (mFGF-21), and to variants thereof and polynucleotides encoding mFGF-21. | 2009-03-19 |
20090074777 | WNT PROTEINS AND DETECTION AND TREATMENT OF CANCER - The present specification provides, inter alia, methods of using Wnt and FZD proteins, genes, FZD and Wnt-specific antibodies and probes in diagnosis and treatment of cancer and for screening test compounds for an ability to treat cancer. Also disclosed are compounds useful for treating cancer such as liver cancer. | 2009-03-19 |
20090074778 | Connective Tissue Growth Factor (CTGF-3) - The present invention relates to a novel connective tissue growth factor-3 protein which is a member of the growth factor superfamily. In particular, isolated nucleic acid molecules are provided encoding the human connective tissue growth factor-3 protein. Connective tissue growth factor-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic and therapeutic methods for detecting and treating connective tissue related disorders. | 2009-03-19 |
20090074779 | NEUROTROPHIN-DERIVED PEPTIDE SEQUENCES - The present invention relates to peptide sequences capable of stimulating neuronal cell differentiation, neural cell survival and neuronal plasticity associated with memory and learning. The peptide sequences of the invention are derived from the proteins belonging to neurotrophic factors, such as NGF, NT3, NT4/5 and BDNF. The invention also relates to pharmaceutical compositions comprising said peptide fragments and uses thereof for treatment of a disease or condition wherein the effects of stimulating neuronal cell differentiation, neuronal cell survival, stimulating neural plasticity associated with learning and memory are beneficial for treatment. | 2009-03-19 |
20090074780 | METHODS OF MODIFYING ANTIBODIES, AND MODIFIED ANTIBODIES WITH IMPROVED FUNCTIONAL PROPERTIES - The invention provides methods of using sequence based analysis and rational strategies to modify and improve the structural and biophysical properties of immunobinders, and in particular of single chain antibodies (scFvs), including such properties as stability, solubility, and/or antigen binding affinity. The invention provides methods of engineering immunobinders, and in particular scFvs, by performing one or more substitutions at amino acid positions identified by analysis of a database of selected, stable scFv sequences, wherein preferred amino acid residues for substitution have been identified. The invention also provides immunobinders prepared according to the engineering methods of the invention. The invention also provides preferred scFv framework scaffolds, into which CDR sequences can be inserted, as well as scFv antibodies made using these preferred framework scaffolds. | 2009-03-19 |
20090074781 | Dengue virus peptide vaccine and methods of preparing and using the same - A consensus peptide sequence designed for domain III of the envelope proteins of four serotypes of dengue virus and used in a vaccine against multiple serotypes of dengue virus is disclosed. The vaccine is able to elicit cross-neutralization antibody responses against multiple serotypes of dengue virus. | 2009-03-19 |
20090074782 | Compositions and Methods for Treating and Diagnosing Cancer - The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells. | 2009-03-19 |
20090074783 | BABESIA SUBTILISIN - Provided is an isolated and purified protein produced by a naturally occurring | 2009-03-19 |
20090074784 | Treatment of chronic viral diseases with antibodies to costimulating polypeptide of T cells - A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the biological activity of the 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, in particular for preventing or treating diseases which involve the immune system, the use of the 8F4 molecule or cells containing the 8F4 molecule as medicaments, in particular for preventing or treating diseases which involve the immune system, and the use of substances which specifically recognize the 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, for diagnosing diseases which involve the immune system. | 2009-03-19 |
20090074785 | Compositions and methods for treatment of colorectal cancer - We have identified a new variant of ileal bile acid binding protein (IBABP), designated IBABP-L, which is a biomarker for colorectal cancer. The transcript for IBABP-L arises from an alternative start site and includes three exons that are absent in IBABP. IBABP-L also shares part of a fourth exon with IBABP. The protein encoded by IBABP-L contains a deduced 49 residue N-terminal sequence that is not found in the IBABP protein. The present invention provides, for example, compositions and methods for diagnosing and treating colorectal cancer. | 2009-03-19 |
20090074786 | FORMULATIONS FOR TREATING OCULAR DISEASES AND CONDITIONS - Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The liquid formulations may comprise rapamycin or other therapeutic agents. | 2009-03-19 |
20090074787 | Anti-CTLA4 Antibody and Indolinone Combination Therapy for Treatment of Cancer - The invention relates to administration of an anti-CTLA4 antibody, particularly human antibodies to human CTLA4, such as those having amino acid sequences of antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, ticilimumab (also referred to as 11.2.1 or CP-675,206), 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and ipilimumab (also referred to as 10D1 or MDX-010), in combination with an indolinone receptor tyrosine kinase inhibitor (RTKI), e.g., N-[2-diethylamino]ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (compound 1), N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (compound 2), and 5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (compound 3), for treatment of cancer. The invention relates to administering a combination of an anti-CTLA4 antibody and an indolinone RTKI such as, inter alia, compound 1. The invention relates to neoadjuvant, adjuvant, first-line, second-line, and third-line therapy of cancer, whether localized or metastasized, and at any point(s) along the disease continuum (e.g., at any stage of the cancer). | 2009-03-19 |
20090074788 | Antibody Against Periostin, and a Pharmaceutical Composition comprising it for Preventing or Treating a Disease in which Periostin is Involved - The present invention provides an antibody against a periostin isoform having anti-cell adhesive activity, especially an anti-periostin antibody having the ability to neutralize anti-cell adhesive properties, as well as a prophylactic or therapeutic agent for periostin-related diseases comprising the antibody. The present invention also provides methods for detecting and quantifying the periostin isoform in a sample by using the antibody, as well as a method for diagnosing periostin-related diseases comprising measuring the amount of the periostin isoform by the detection or quantification method. | 2009-03-19 |
20090074789 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND CONDITIONS - The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, particularly ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation, and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against the bioactive lipid, sphingosine-1-phosphate, and its variants, which moieties are capable of decreasing the effective concentration of bioactive lipid being targeted. In one embodiment, the immune-derived moiety is a humanized monoclonal antibody that is reactive against sphingosine-1-phosphate. | 2009-03-19 |
20090074790 | Methods for measuring transforming growth factor beta (TGF-beta) receptor signaling activity and uses thereof - Methods are disclosed for determining the optimal biologic dose of a TGFβ receptor kinase inhibitor for administration to patients in need of such therapy and for monitoring the effectiveness of therapy with a TGFβ receptor kinase inhibitor in patients receiving such therapy. Kits comprising antibodies and reagents useful in such methods are also disclosed. | 2009-03-19 |
20090074791 | Phenylisoquinoline and Phenylquinazoline Derivatives - The present invention relates to substituted phenylisoquinoline and phenylquinazoline derivatives and to their pharmaceutical uses in preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable. | 2009-03-19 |
20090074792 | Compositions containing full-length L1R nucleic acid and endoplasmic reticulum-targeting sequence, and methods of use - The invention described here encompasses DNA and protein vaccines against poxviruses, and relevant immunogenic compositions, comprising at a minimum a nucleic acid encoding a modified full-length poxvirus L1R gene or its ortholog. The L1R gene is modified so that an endoplasmic reticulum-targeting sequence is operably linked on the 5′ end. Preferably the nucleic acid sequences for other poxviruses antigens are also included, such as A33R, B5R and/or A27L. These vaccines and compositions provide improved neutralizing antibody response elicited by molecular poxvirus vaccines, over known vaccines using unmodified L1R. | 2009-03-19 |
20090074793 | High Affinity Human Antibodies to Human IL-4 Receptor - An isolated human antibody or antibody fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4Rα) with high affinity (K | 2009-03-19 |
20090074794 | Anti-TNF Antibodies, Compositions, Methods and Uses - The present invention relates to inhibiting TNF in patients having rheumatoid arthritis, psoriatic arthritis or ankylosing spondilitis, by administering anti-TNF antibodies comprising the heavy chain variable region of SEQ ID NO: 7 and the light chain variable region of SEQ ID NO:8, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof. | 2009-03-19 |
20090074795 | Methods for addressing ocular diseases through interference with the wnt signaling pathway - Choroidal neovascularization (CNV) in age-related macular degeneration (AMD) is a leading cause of blindness. Very low-density lipoprotein receptor gene knockout (Vldlr | 2009-03-19 |
20090074796 | Pde5 inhibitor compositions and methods for immunotherapy - The invention features methods and compositions featuring a PDE5 inhibitor for treating or preventing immunological-mediated disease in a subject. | 2009-03-19 |
20090074797 | NOVEL GENE UPREGULATED IN CANCERS OF THE PROSTATE - The present invention relates to a novel protein designated 20P2H8 which shares homology with several heterogeneous nuclear ribonucleoproteins (hnRNPs). A full length approximately 3600 bp 20P2H8 cDNA (SEQ ID NO: 1, encoding a 517 amino acid open reading frame (SEQ ID NO: 2), is provided herein. | 2009-03-19 |
20090074798 | System and method for the production of recombinant glycosylated proteins in a prokaryotic host - A system and a method for the production of recombinant N-glycosylated target proteins. The system comprises a prokaryotic organism (e.g. | 2009-03-19 |
20090074799 | ANTIBODIES TO CLASS II CYTOKINE RECEPTOR-7 - Antibodies to novel receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise an extracellular domain of a cell-surface receptor that is expressed in kidneys, pancreas, prostate, adrenal cortex and nervous tissue. The polypeptides may be used within methods for detecting ligands that promote the proliferation and/or differentiation of these organs. | 2009-03-19 |
20090074800 | Cancer antigen and use thereof - An object of the present invention to provide: a human pancreatic cancer antigen and/or a human colon cancer antigen that can be applied to the diagnosis and/or treatment of various types of cancers or tumors including pancreatic cancer and colon cancer as representative examples; a gene encoding the same; an anti-cancer vaccine using the same; or the like. The present invention provides a cancer antigen comprising a protein having the amino acid sequence shown in SEQ ID NO: 1; a peptide comprising a portion of said protein and having immune-stimulating activity; an anti-cancer vaccine comprising said peptide; a DNA having the nucleotide sequence shown in SEQ ID NO: 2, or its complementary sequence or a part or full length of these sequence; an anti-cancer vaccine comprising said DNA; and use thereof. | 2009-03-19 |
20090074801 | HYPOALLERGENIC ALLERGY VACCINES BASED ON THE TIMOTHY GRASS POLLEN ALLERGEN PHL P 7 - The present invention pertains to polypeptides derived from the timothy grass pollen allergen Phl p 7. The polypeptides display reduced allergen activity and are useful as allergy vaccines for the treatment of sensitized allergic patients and for prophylactic vaccination. | 2009-03-19 |
20090074802 | IMMUNOMODULATING OLIGOPEPTIDES - The invention provides immunomodulating peptides of the general formula X—P—Y, preferably I—P—Y, and/or oligopeptides comprising this amino acid sequence and/or conjugates with these peptides. Also provided are pharmaceutical compositions with these peptides and conjugates. | 2009-03-19 |
20090074803 | IMMUNOGEN PLATFORM - Aspects of the present invention relate to chimeric polypeptides including HCV NS3/4A sequences and T-cell epitopes. Embodiments include nucleic acids encoding the chimeric NS3/4A polypeptides, the encoded polypeptides, compositions containing said nucleic acids, compositions containing said chimeric polypeptides, as well as methods of making and using the aforementioned compositions including, but not limited to medicaments and vaccines. | 2009-03-19 |
20090074804 | VERO CELL-BASED INFLUENZA VIRUS STRAINS AND VACCINES - The present invention relates to isolated influenza virus strains suitable for increased vaccine production for mammals. The influenza virus strains contain at least one modified influenza protein that results in increased production of the influenza virus from a mammalian host cell, such as a vero cell. The present invention also relates to the vaccines produced from the influenza virus strains. The present invention further relates to isolated modified influenza proteins and isolated nucleic acid molecules that encode for the modified influenza proteins. | 2009-03-19 |
20090074805 | Yeast-based Therapeutic for Chronic Hepatitis C Infection - Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection. | 2009-03-19 |
20090074806 | NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STREPTOCOCCUS PNEUMONIAE FOR DIAGNOSTICS AND THERAPEUTICS - The invention provides isolated polypeptide and nucleic acid sequences derived from | 2009-03-19 |
20090074807 | MORAXELLA (BRANHAMELLA) CATARRHALIS ANTIGENS - The present invention relates to polypeptides of | 2009-03-19 |
20090074808 | Secreted Streptococcus Pneumoniae Proteins - Novel proteins from | 2009-03-19 |
20090074809 | Composition of entomopathogenic fungus and method of production and application for insect control - Microsclerotia of entomopathogenic fungi, including | 2009-03-19 |
20090074810 | Modified Adenovirus Hexon Protein and Uses Thereof - The present invention provides a method of altering the specificity of an adenovirus vector. The method involves providing an adenovirus having a capsid with a modified adenovirus hexon protein. The modified adenovirus has a capsid comprising a hexon protein with a deletion in hypervariable region 1 and/or hypervariable region 4 of the hexon and an insert of an exogenous molecule therein. | 2009-03-19 |